- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
CAS 2023
Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers
Qin Mei, George Wang, Jieying Liu, Yunying Chen, Jijie Gu, and Siwei Nie
Biologics Innovation and Discovery, WuXi Biologics
| Anti-CD3 based T cell engager antibodies can redirect cytotoxic activity of T cells in a non-MHC restricted fashion to kill tumor cells effectively. Therefore, the discovery of an anti-CD3 antibody capable of activating T cells in the presence of tumor cells is highly desirable and in recent years, many anti-CD3 bispecific antibodies (bsAbs) entered clinical trials. Here, we showcase the discovery of an anti-CD3 monoclonal antibody (mAb) specific to a unique epitope on the epsilon chain of CD3 originating from the WuXi Biologics advanced hybridoma platform. |  |
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?